DPDPE

Summary

DPDPE (Tyr-[D‑Pen‑Gly‑Phe‑D‑Pen]) is a cyclic peptide that acts as a selective agonist at delta‑opioid receptors. It is employed in pre‑clinical research to explore delta‑opioid signalling, receptor regulation, and reward mechanisms. Studies have examined its structural conformation, its lack of antitussive activity, and its reinforcing properties when injected into brain reward sites.

Mechanism of Action

DPDPE binds with high affinity to the delta‑opioid receptor (DOR), a G‑protein‑coupled receptor that couples to G i/o proteins. Activation inhibits adenylate cyclase, lowering intracellular cAMP and reducing neuronal excitability. Chronic exposure leads to receptor desensitization and down‑regulation, as shown by altered receptor localisation and reduced cAMP responses. X‑ray studies reveal a cyclic backbone that stabilises the active conformation required for DOR engagement.

What the Research Shows

Animal experiments show that DPDPE does not suppress cough, indicating delta‑opioid activation alone is insufficient for antitussant effects. Cellular studies in CHO cells expressing human DOR demonstrate that chronic DPDPE exposure can trigger receptor down‑regulation, which is abolished when the receptor’s C‑terminal tail is truncated, and leads to functional desensitisation of cAMP signalling. Structural work confirms a defined cyclic conformation for DPDPE, facilitating its selectivity. Intracranial self‑administration studies reveal that DPDPE is self‑infused into the ventral tegmental area, producing reinforcing effects comparable to other opioids, highlighting its utility in reward‑pathway research.

Reported Benefits

DPDPE provides a valuable tool for dissecting delta‑opioid receptor pharmacology, including ligand‑induced receptor trafficking, tolerance mechanisms, and reward circuitry. Its selective action allows researchers to differentiate delta‑mediated effects from mu‑ and kappa‑opioid pathways, and its defined cyclic structure aids in structure‑activity relationship studies.

Limitations of the Evidence

No antitussive or therapeutic efficacy has been demonstrated; effects are confined to rodent models. Tolerance and receptor down‑regulation develop with repeated use, limiting its utility for chronic studies. Human data are absent, and safety or pharmacokinetic information is not reported in the literature. Consequently, DPDPE remains a research‑only compound.

Safety Considerations

Safety data for DPDPE are limited to pre‑clinical observations. As a delta‑opioid agonist, it may share class‑related risks such as tolerance, dependence, and reinforcing properties, as indicated by self‑administration studies. No specific adverse events or toxicology profiles are described in the cited abstracts, so caution is advised when extrapolating to potential human use.

How It Is Administered

DPDPE has been administered to laboratory animals via intracerebroventricular, intrathecal, intravenous, and subcutaneous routes. Formulations are typically aqueous peptide solutions prepared for injection in controlled experimental settings.

Routes of Administration

Goals & Uses

• Analgesia (preclinical)Pain / NociceptionHigh
• Cardioprotection (preclinical)Cardiovascular ResearchModerate
• analgesia researchPainModerate
• Mood and antidepressant effects (preclinical)Neuropsychiatry ResearchModerate
• Neuroprotection (preclinical)Neuroscience ResearchModerate
• Delta-opioid receptor characterizationResearch / PharmacologyHigh
• neuropsychiatric studiesMoodLow
• opioid receptor selectivity profilingPharmacologyHigh

Contraindications

• Known hypersensitivity to enkephalin analoguesAllergy/ImmunologyHigh
• Human therapeutic useRegulatory/safetyHigh

Adverse Effects

• Convulsions/SeizuresNeurologicalUncommon
• Cardiovascular effectsCardiovascularUnknown
• ConstipationGastrointestinalUnknownReduced bowel frequency or difficulty passing stool
• Tolerance developmentPharmacologicalCommon
• Respiratory depressionRespiratoryUnknown
• SedationCNSCommon

Drug Interactions

• CNS depressantsModerate
• Mu-opioid receptor agonists (e.g., morphine)Moderate
• Naltrindole (delta-opioid antagonist)High
• Other opioid agonistsModerate

Population Constraints

• HumansRegulatory / SafetyAbsolute
• Pregnant or lactating animalsReproductiveRelative
• Human subjectsRegulatory/SafetyAbsolute

Regulatory Status

• European UnionInvestigationalNo marketing authorization; used in scientific research.
• United StatesInvestigationalResearch chemical, not FDA-approved.
• United KingdomUnapprovedNot approved by MHRA; controlled under UK drug regulations as an opioid analogue for research purposes only.

Not approved for human therapeutic use; classified as a research chemical.

Evidence & Sources

• [Mechanisms of central antitussives]
  Journal ArticleModerateKamei J1998-01-01T00:00:00.000000Z
• The molecular mechanisms of cellular tolerance to delta-opioid agonists. A minireview
  Journal ArticleModerateVarga EV2003-01-01T00:00:00.000000Z
• Role of opioidergic and serotonergic mechanisms in cough and antitussives
  Journal ArticleModerateKamei J1996-01-01T00:00:00.000000Z
• Structural studies of opioid peptides: a review of recent progress in x-ray diffraction studies
  Journal ArticleModerateDeschamps JR, George C, Flippen-Anderson JL1996-01-01T00:00:00.000000Z
• Endogenous opiates and behavior: 2012
  Journal ArticleModerateBodnar RJ2013-01-01T00:00:00.000000Z
• Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies
  Journal ArticleModerateMcBride WJ, Murphy JM, Ikemoto S1999-01-01T00:00:00.000000Z

Frequently Asked Questions